Faculty David Raulet and Aduro Biotech Collaborators published their research, SLC19A1 transports immunoreactive cyclic dinucleotides, in Nature on September 11, 2019. This research has landmark implications for immunotherapeutic treatment of cancer, host responsiveness to CDN-producing pathogenic microorganisms, and possibly for some inflammatory diseases.
To read the paper entirely, you can go here.